Articles tagged with Prostate Cancer
A study published in JAMA Oncology found high rates of inappropriate imaging for both prostate cancer and breast cancer, suggesting that regional culture and infrastructure play a role in health care utilization patterns. The researchers estimated that 30% of healthcare resources in the US do not improve patient health.
A new study from NYU Langone Medical Center found that over 40% of low-risk prostate and breast cancer patients in certain US regions received inappropriate tests. The research suggests that regional culture and infrastructure play a significant role in the use of imaging tests, with some areas exhibiting more appropriate use than others.
A family history of prostate cancer in first-degree relatives increases breast cancer risk by 14%, according to a study of 78,171 women. Women with both breast and prostate cancer histories face an almost 2-fold increase in breast cancer risk
New research shows that non-cancerous prostate cells with genetic mutations can develop into cancer, potentially explaining why prostate cancer often has multiple genetically different tumours. This discovery could lead to a rethink of treatment strategies and improve outcomes for men with the disease.
A study by the University of Exeter found that black men are less likely to opt for prostate cancer investigation due to fear and perception of severe complications. The research suggests that proactive discussion with doctors and targeted education may help address this issue.
A comprehensive, population-based regional health care management program for men with prostate cancer has led to improved outcomes. The program includes safety-net screening programs, improved surgical procedures, and enhanced drug management, resulting in lower rates of blood loss and osteoporosis-related complications.
A case-control study of over 180,000 men found that men with testicular cancer have a higher incidence of prostate cancer compared to those without a history of the disease. The study revealed a significant increase in aggressive prostate cancers among men with testicular cancer.
A retrospective analysis of 87,500 men treated for prostate cancer found a notable increase in intermediate- and high-risk cases between 2011 and 2013. This trend could lead to 1,400 additional prostate cancer deaths per year if confirmed through further research.
A study of 945 patients with intermediate-risk prostate cancer found nearly four-fold higher mortality risk within 15 years compared to low-risk patients. The analysis suggests that active surveillance may not be suitable for all intermediate-risk patients, emphasizing the need for personalized treatment approaches.
A small prospective study found no significant difference in treatment outcomes between patients with AR-V7-positive and -negative metastatic castration-resistant prostate cancer who received taxane chemotherapy. PSA responses were achieved in 41% of both groups.
Men with favorable intermediate-risk prostate cancer may be candidates for active surveillance, with no significantly increased risk of death compared to those with low-risk PC. The study found that the absolute estimates of PC-specific mortality were less than one percent in men with both low-risk and favorable intermediate-risk PC.
Keck Medicine researchers found that GPR158 promotes prostate cancer cell growth and is associated with neuroendocrine transdifferentiation, leading to tumor progression. Elevated expression of GPR158 is linked to recurrence in prostate cancer patients.
A Purdue University study found that a combination of low doses of metformin and gene inhibitor BI2536 can successfully halt the growth of late-stage prostate cancer tumors, potentially prolonging patients' lives. The treatment promotes self-destruction of cancer cells and prevents androgen synthesis.
Researchers at Ohio State University found that androgen receptor activates different genes when bound to antiandrogens, suggesting new targets for prostate cancer treatment. Antiandrogen response elements were discovered, which activate oncogenes relevant to tumor progression.
A study of over 1,000 men found that targeted fusion-guided biopsy is more effective in detecting high-risk prostate cancer than standard biopsy. This method combines MRI and ultrasound images to pinpoint suspicious areas and diagnose cancers with greater accuracy.
A targeted magnetic resonance/ultrasound fusion biopsy detected more high-risk prostate cancers and fewer low-risk cancers compared to standard biopsy. The study found that adding standard biopsy to targeted biopsy provided limited benefits in detecting additional high-risk tumors.
Patients with a history of smoking have increased risks of cancer relapse, side effects, and death from prostate cancer, according to a study published in BJU International. Smoking negatively affects prostate cancer health outcomes, particularly when treated with radiotherapy.
The Cleveland Clinic has received a $1 million grant to advance the treatment of lethal prostate cancer by identifying genetic biomarkers. The research aims to detect treatment-resistant prostate cancer at an early stage, improving treatment outcomes for patients.
Researchers at Oregon State University have identified sulforaphane's ability to selectively kill cancer cells and alter gene expression in metasticized prostate cancer. The compound may work alongside existing approaches to treat advanced prostate cancer, with potential for therapeutic value.
Researchers at Huntsman Cancer Institute have developed a new tool to estimate prostate cancer risk based on family history, which can help clinicians decide whether a PSA test is appropriate. The study found that two-thirds of Utah men have some increased risk of developing prostate cancer due to their family history.
A new study found that high-dose testosterone therapy can suppress advanced prostate cancers and reverse resistance to testosterone-blocking drugs. Seven of the 14 men showed a significant decrease in PSA levels, while four stayed on testosterone therapy for up to 24 months with continued low PSA levels.
A novel imaging technique called restriction spectrum imaging-MRI (RSI-MRI) has been developed to improve the accuracy of prostate cancer detection. RSI-MRI corrects for magnetic field distortions and focuses on water diffusion within tumor cells, providing a more refined sense of the tumor's extent.
A new study found that adding radiation treatment to hormone therapy saves more lives among older men with locally advanced prostate cancer, reducing cancer deaths by nearly 50 percent. The treatment was also associated with fewer deaths from any cause.
Researchers found that SIRT1 enzyme loss drives early prostate cancer formation in mouse models. The study suggests SIRT1 may be a target for prostate cancer prevention.
Researchers discovered a protein called BAZ2A that influences epigenetic patterns in prostate cancer cells, leading to increased malignancy and tumor growth. High levels of BAZ2A expression were linked to more advanced tumors, metastases, and poor patient outcomes.
Researchers at Georgetown University Medical Center show that YK-4-279 prevents tumor growth and spread in mice with prostate cancer harboring a common chromosomal abnormality. The agent targets the ETS fusion, producing new genes that push cancer cells to become more aggressive.
A new study published in European Urology has found that androgen deprivation therapy (ADT) is associated with decreased survival in men with localized prostate cancer, particularly those with longer life expectancies. The research highlights the need to reconsider the use of ADT as a primary treatment for low-risk or localized cancers.
A study found that prescriptions for bisphosphonates remain low even among men at high risk of fractures on androgen deprivation therapy. The study suggests limited awareness among clinicians about optimal bone health management, particularly in men with prior osteoporosis or fragility fracture.
The Prolaris test could save the healthcare system $6 billion over 10 years by reducing costs and improving health outcomes. The test improves health outcomes, reduces healthcare costs, and aids physicians in providing clinical care for their patients.
Researchers have found that blocking the CCR5 receptor with an HIV drug can significantly reduce metastasis to the bone in prostate cancer. This breakthrough suggests a potential new treatment approach for patients with advanced prostate cancer.
Conventional treatments such as surgery and radiotherapy are less effective in prostate cancer patients carrying BRCA mutations, resulting in lower survival rates. The study suggests that targeted therapy, like PARP inhibitors, may be a more suitable option for these patients.
Researchers at UC Davis found that diets rich in whole walnuts or walnut oil slowed prostate cancer growth in mice. The walnut diet also reduced levels of the hormone IGF-1, which had been previously implicated in both prostate and breast cancer.
Researchers developed a genetic test to identify men at highest risk of prostate cancer recurrence after localized treatment. The test analyzes biopsy tissue and tumor oxygen content to predict disease return with 80% accuracy, enabling personalized treatment plans.
A new study shows a novel molecular imaging drug is effective in detecting early prostate cancer in soft tissue, lymph nodes, and bone. The drug, Tc-99m MIP-1404, has favorable pharmacokinetics and biodistribution, representing a breakthrough in prostate cancer imaging.
A molecular breakthrough has identified a compound that can inhibit the activity of SRPK1, a molecule key to tumor formation and blood vessel creation. This process is essential for cancer cell survival and multiplication.
Researchers at UT Arlington are developing tissue-engineered artificial lymph nodes that can attract prostate cancer cells, allowing for more targeted treatments and potentially longer patient survival. The technology, led by Liping Tang, could also help identify the biological signals that enable cancer to migrate throughout the body.
A recent study found that androgen deprivation therapy (ADT) increases the risk of heart-related deaths in men with congestive heart failure or prior heart attacks. The study analyzed data from 5,077 men with prostate cancer, revealing a 3.3-times increased risk of heart-related deaths in this subgroup.
Researchers have developed a device that can detect markers of kidney disease and prostate cancer in urine samples, offering instant results and potentially higher accuracy. The device uses DNA sequences to latch onto disease markers, allowing for early detection at ultra-low concentrations.
The Canadian Task Force on Preventive Health Care recommends against using the PSA test to screen for prostate cancer in most men, citing an increased risk of false positives and overdiagnosis. The guideline aims to balance potential benefits with substantial harms.
A new study found that two-thirds of health websites recommending prostate cancer screening aligns with medical organizations' stance. Many online resources advocate for patient-individualized approaches, while some sites advise against screening due to potential risks.
Research suggests that men who have slept with more than 20 women may have a lower risk of prostate cancer, while those with multiple male partners are at higher risk. The study found a 28% reduction in prostate cancer risk for men with many female partners and a twofold increase in risk for those with multiple male partners.
A University of Colorado Cancer Center study found that vitamin D upregulates GDF-15, a gene suppressing inflammation in prostate tissue. This suggests vitamin D could be used to target NFkB, promoting tumor suppression.
Prostate cancer cells hoard copper, and researchers have found a way to deliver a trove of copper along with a drug that selectively destroys the diseased cells. This combination approach could lead to improved treatments for late-stage disease.
A study published in Cancer Epidemiology, Biomarkers & Prevention found that men with high cholesterol and triglyceride levels after prostate cancer surgery had a higher risk of disease recurrence. Normalizing lipid levels may reduce this risk.
A new study identifies a set of RNA molecules in urine and tissue samples that can detect prostate cancer with high sensitivity and specificity. These long noncoding RNAs have the potential to serve as biomarkers for early detection and diagnosis of prostate cancer, offering a promising approach to reduce overtreatment and morbidity.
Researchers at MD Anderson Cancer Center identified a genetic variant near the KLK3 gene that can predict aggressive prostate cancer in GS7 patients. The study found a single nucleotide polymorphism (SNP) on the KLK3 gene associated with disease aggression, providing potential biomarkers for personalized treatment.
A novel robotic system is being tested to determine if it can make prostate cancer biopsies faster, more accurate, less costly, and less discomforting for patients. The robot uses real-time MRI images to guide the insertion of needles, potentially delivering therapies with greater precision.
A new study led by Henry Ford researchers found that guidelines recommending against routine prostate cancer screening in elderly men have had little effect. The study analyzed data from the 2012 Behavioral Risk Factor Surveillance System and found significant variability in PSA screening rates across states and regions.
Researchers at Moffitt Cancer Center have discovered 23 new regions of the genome linked to prostate cancer risk, with testing potentially identifying men with a six times higher risk. This brings the total number of genetic variants linked to prostate cancer to 100.
A major new study shows that some prostate cancer treatments can stop working over time and even drive tumour growth. Researchers identified a 'treatment paradigm' using repeated blood samples to monitor signs of therapy becoming counter-productive.
A global team of scientists has found 23 new genetic variants associated with an increased risk of prostate cancer. The study, which analyzed data from over 87,000 men, suggests that these variants may be important in regulating genes rather than making proteins.
Researchers analyzed data from over 17,000 surveys to track changes in urinary and sexual symptoms following various prostate cancer treatments. The study found that certain treatments, such as surgery and low-dose rate brachytherapy (LDR), may cause temporary increases in symptoms, while others, like intensity modulated radiation ther...
A phase I/II trial of hypofractionated radiation therapy found that prostate cancer patients reported similar quality of life, bladder and bowel function before and after treatment. The study's results also indicated that different regimens of hypofractionated RT produced similar outcomes in terms of patient-reported quality of life.
A global study of 80,000 men with prostate cancer has identified another 23 prostate cancer risk loci, bringing the total to 100 genetic regions associated with the disease. The study found that these genetic variants explain 33% of familial risk and can be used to predict aggressive form of prostate cancer.
A large cohort analysis found a significant link between male pattern baldness and aggressive prostate cancer. Men with specific hair loss patterns at age 45 were at a 40% increased risk of developing aggressive prostate cancer. The study supports earlier research suggesting a biological link between baldness and prostate cancer.
A genetic discovery has led to a highly accurate test for aggressive prostate cancer recurrence, identifying new avenues for treatment. The test is 91 percent accurate and could potentially lead to a cure through genetic therapy.
A global study of over 87,000 individuals from diverse ethnic backgrounds has discovered 23 new genetic factors that contribute to the development of prostate cancer. The research, led by Keck School of Medicine at USC, provides valuable insights into the causes of this disease and may lead to better prevention strategies.
A major international study identified 23 new genetic variants associated with increased risk of prostate cancer, explaining a third of the inherited risk. Testing for these variants can identify 1% of men with a risk almost six times as high as the population average.
Researchers at Memorial Sloan Kettering Cancer Center have successfully grown prostate cancer organoids from human tumors, providing a new tool for testing cancer drugs and personalizing treatment. The addition of these organoids doubles the number of existing prostate cancer cell lines, offering a more accurate representation of the d...
A blood test detecting the 'nicked' protein AR-V7 in prostate cancer patients can predict resistance to commonly used treatments enzalutamide and abiraterone. This biomarker may help tailor treatment strategies for men with detectable levels of AR-V7.